Last $197.39 USD
Change Today -1.99 / -1.00%
Volume 1.5M
ACT On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Open
$198.49
Previous Close
$199.38
Day High
$200.88
Day Low
$195.37
52 Week High
02/26/14 - $230.77
52 Week Low
04/18/13 - $96.52
Market Cap
34.4B
Average Volume 10 Days
3.4M
EPS TTM
$3.46
Shares Outstanding
174.5M
EX-Date
--
P/E TM
57.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Related Businessweek News

View More BusinessWeek News

actavis plc (ACT) Details

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

19,200 Employees
Last Reported Date: 02/25/14
Founded in 1983

actavis plc (ACT) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $2.6M
Chief Financial Officer of Global
Total Annual Compensation: $557.3K
President of Global Operations
Total Annual Compensation: $639.5K
Director and President of Actavis Pharma
Total Annual Compensation: $735.6K
President of Actavis Global Research and Deve...
Total Annual Compensation: $651.7K
Compensation as of Fiscal Year 2013.

actavis plc (ACT) Key Developments

Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation

Actavis plc announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(R) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(R) FE under its pending Abbreviated New Drug Application (ANDA) beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd. in connection with Lupin's pending ANDA for a generic version of Generess(R).

Actavis plc Launches New Regional Office in Singapore

Actavis plc announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region. In addition, Actavis announced that its subsidiary operating in Singapore, Drug Houses of Australia Pte Ltd, (DHA), will be transitioned to the Actavis brand.

Particle Sciences Enters into an Exclusive Agreement with Actavis plc

Particle Sciences announced that they have entered into an exclusive agreement with Actavis plc to develop an unnamed complex generic product. Under the agreement, Particle Sciences is responsible for design, formulation and cGMP supplies. Actavis will have responsibility for clinical testing, regulatory filings and marketing. Under the terms of the agreement, Particle Sciences will receive undisclosed milestone and revenue- based payments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $197.39 USD -1.99

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $133.92 USD +2.46
Astellas Pharma Inc ¥1,139 JPY -1.00
Covidien PLC $69.86 USD +0.02
Shire PLC 2,925 GBp +25.00
Valeant Pharmaceuticals International Inc C$134.45 CAD +0.80
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 3.6x
Price/Cash Flow 373.2x
TEV/Sales 2.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.